New schizophrenia drug shows promise in bioequivalence trial
NCT ID NCT07268430
First seen Dec 16, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study compared a new generic version of paliperidone palmitate injection to the standard brand-name drug in 256 Chinese adults with schizophrenia. The goal was to see if the new version reaches similar levels in the blood, meaning it should work just as well. Participants received multiple injections over time, and researchers measured drug levels and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anding Hospital Capital Medical University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.